CA
NZ
UK
AU
IND
US
Eupraxia moved from an implied CAD 10.63 to CAD 9.66 on 45.74 thousand shares, 0.40 times average. The shares also trade in the United States, where they closed near USD 7.46 on October 12 after an October high of USD 9.12, a drop of …
● MDT shares rose 3.90% to $91.93 in Monday’s session on 36.56 million shares, about $3.36 billion traded and 18th among US stocks.
No company release dated October 13 was found in company filings and wire releases reviewed, so the most relevant recent updates are summarized here. DataMeds AI, a Tampa-based health IT company that changed its name from Wellgistics Health in July and moved its ticker …
No company release dated October 13 was found in company filings and wire releases reviewed, so the most relevant recent updates are summarized here. MacroGenics reported its second-quarter 2026 results on August 13, with total revenue of USD 32.8 million compared with USD 6.9 …
Mobile-health Network Solutions fell 25.00% pre-market after a roughly 370% spike on October 12, with no catalyst found, on 1.083 million shares. The stock closed near USD 0.85 on October 9 and traded as high as about USD 4 on October 12, so the …
Moderna fell 4.30% pre-market, with European quotes near EUR 190.49 on October 13 versus EUR 202.00 on October 12, and no new company release was found. The next catalyst is the full intismeran data at ESMO's Presidential Symposium, with an investor event on October …
No company release dated October 13 was found in company filings and wire releases reviewed, so the most relevant recent updates are summarized here. Obsidian Therapeutics began trading on Nasdaq as OBX on August 4, 2026 after completing its merger with Galera Therapeutics alongside …
No company release dated October 13 was found in company filings and wire releases reviewed, so the most relevant recent updates are summarized here. Olema reported on August 10 that enrollment in the pivotal Phase 3 OPERA-01 trial of palazestrant monotherapy in second- and …
No company release dated October 13 was found in company filings and wire releases reviewed, so the most relevant recent updates are summarized here. Picard Medical is the parent of SynCardia Systems, maker of the SynCardia Total Artificial Heart, which is approved by both …
The screener tags a product or partnership item for Prelude, but the specific October 13 announcement was not located in company filings or wire releases reviewed. Prelude's most recent update, on August 11, showed R&D expense falling to USD 16.1 million from USD 25.8 …
Please wait processing your request...